Heidelberg Pharma GmbH

Newsletter

 

Heidelberg Pharma is the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology. This proprietary technology platform is being applied to develop the company’s own therapeutic ATACs as well as in third-party ADC collaborations to create more effective and specific anti-cancer drugs. In addition, Heidelberg Pharma offers preclinical services with a focus on explorative pharmacology in oncology, autoimmunity and inflammation along with bioanalytical methods.

 

Rosenhof LadenburgNews & Events: June 2017

Heidelberg Pharma Signs Exclusive Multi-target Research Agreement with Takeda for the Development of Antibody Targeted Amanitin Conjugates [...]